Suchergebnisse - "Robichaux, Jacqulyne"

PubPharm (4)

1

Poziotinib for EGFR exon 20-mutant NSCLC : Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity

enthalten in: Cancer cell | 2022

von Elamin, Y. | Robichaux, J. | Carter, B. | +24

CommentIn: Cancer Cell. 2022 Jul 11;40(7):705-708. - PMID 35820394

2

Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer : Results From a Phase II Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Elamin, Y. | Robichaux, J. | Carter, B. | +13

CommentIn: J Clin Oncol. 2022 Mar 1;40(7):693-697. - PMID 35072488

3

Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity

enthalten in: Cancer cell | 2019

von Robichaux, J. | Elamin, Y. | Vijayan, R. | +28

ErratumIn: Cancer Cell. 2020 Mar 16;37(3):420. - PMID 32183953

4

Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer

enthalten in: Nature medicine | 2018

von Robichaux, J. | Elamin, Y. | Tan, Z. | +21

CommentIn: Nat Rev Clin Oncol. 2018 Jul;15(7):404. - PMID 29743681

1
[1]